MedPath

Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd. logo
🇦🇺Australia
Ownership
Public
Established
2014-01-01
Employees
51
Market Cap
-
Website
http://www.paradigmbiopharma.com

Clinical Trials

3

Active:0
Completed:1

Trial Phases

2 Phases

Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (50.0%)
Phase 3
1 (50.0%)

A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

Phase 3
Recruiting
Conditions
Osteoarthritis, Knee
Interventions
Drug: Pentosan Polysulfate Sodium twice weekly
Drug: Placebo
First Posted Date
2025-04-08
Last Posted Date
2025-07-22
Lead Sponsor
Paradigm Biopharmaceuticals Ltd.
Target Recruit Count
466
Registration Number
NCT06917404
Locations
🇺🇸

Conquest Research, Winter Park, Florida, United States

🇺🇸

Physician Research Collaboration, Lincoln, Nebraska, United States

🇦🇺

Sportsmed Biologic LTD, Box Hill, Victoria, Australia

Treatment and Duration Effect of Pentosan Polysulfate Sodium (PPS) in Participants With Knee Osteoarthritis Pain

Completed
Conditions
Osteoarthritis, Knee
Interventions
Drug: Pentosan Polysulphate Sodium
Drug: Placebo (Sodium Chloride Injection, 0.9%)
First Posted Date
2021-03-24
Last Posted Date
2025-07-22
Lead Sponsor
Paradigm Biopharmaceuticals Ltd.
Target Recruit Count
133
Registration Number
NCT04814719
Locations
🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

🇦🇺

Emeritus Research, Camberwell, Victoria, Australia

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.